Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Appoints Jerald Korn as General Counsel and Corporate Secretary
July 22, 2019 08:00 ET | Kaleido Biosciences
LEXINGTON, Mass., July 22, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Appointment of Theo Melas-Kyriazi to its Board of Directors
July 15, 2019 08:00 ET | Kaleido Biosciences
LEXINGTON, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Highlight Chemistry-Driven Approach at Microbiome Movement – Drug Development Summit
June 26, 2019 08:00 ET | Kaleido Biosciences
Members of leadership team to participate in sessions discussing the role of the microbiome in human disease Summit coincides with World Microbiome Day: June 27, 2019 LEXINGTON, Mass., June 26,...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
June 03, 2019 08:00 ET | Kaleido Biosciences
LEXINGTON, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 02, 2019 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Presentation of Clinical Study and Ex Vivo Data Supporting the Development of Novel Microbiome Metabolic Therapies for Hyperammonemia at The International Liver Congress™ 2019 (EASL)
April 12, 2019 07:30 ET | Kaleido Biosciences
LEXINGTON, Mass., April 12, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Key Appointments to Leadership Team
April 08, 2019 08:00 ET | Kaleido Biosciences
LEXINGTON, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Upcoming Presentations at the Society for Inherited Metabolic Disorders Annual Meeting and The International Liver Congress™ (EASL)
March 27, 2019 08:15 ET | Kaleido Biosciences
Posters to feature ex vivo and in-human data supporting Kaleido’s Microbiome Metabolic Therapy programs for the treatment of hyperammonemia LEXINGTON, Mass., March 27, 2019 (GLOBE NEWSWIRE) --...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Initiation of Dosing in Non-IND Clinical Studies in Patients with Urea Cycle Disorders and Cirrhosis
March 21, 2019 08:00 ET | Kaleido Biosciences
Studies are evaluating novel Microbiome Metabolic Therapies, KB195 and KB174, in target patient populations; data expected in Q4 2019 Third non-IND clinical study in healthy subjects also underway to...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Highlight its Platform to Identify and Evaluate Microbiome Metabolic Therapies to Reduce Gut Ammonia Production in Presentation at Keystone Symposia on Microbiome
March 08, 2019 08:30 ET | Kaleido Biosciences
LEXINGTON, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...